CONMED Corporation (CNMD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CONMED Corporation (CNMD) trades at $35.57 with AI Score 73/100 (Grade A). CONMED Corporation develops, manufactures, and sells surgical devices and related equipment globally. Market cap: $1.07B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for CNMD: CNMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNMD against Healthcare peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.
CNMD: 1/1 perspectives are bullish.
How is this calculated? →CONMED Corporation (CNMD) Healthcare & Pipeline Overview
CONMED Corporation, a medical technology company, specializes in surgical devices and equipment, offering orthopedic and general surgery solutions. With a focus on minimally invasive procedures and a direct-to-hospital sales model, CONMED serves a global market, maintaining a competitive position through product innovation and established brands.
What Is the Investment Thesis for CNMD?
CONMED Corporation presents a compelling investment case due to its established position in the medical devices market and its focus on surgical solutions. With a market capitalization of $1.07B and a P/E ratio of 20.3, CONMED demonstrates financial stability. The company's gross margin of 53.6% indicates efficient operations and strong pricing power. Growth catalysts include continued innovation in orthopedic and general surgery products, expansion into emerging markets, and strategic acquisitions. Key value drivers are the increasing demand for minimally invasive surgical procedures and the aging global population. Potential risks include competition from larger medical device companies and regulatory changes in the healthcare industry. The company's dividend yield of 1.09% provides a modest return for investors.
Based on FMP financials and quantitative analysis
CNMD Key Highlights
- Market Cap of $1.07B reflects CONMED's established position in the medical devices market.
- P/E Ratio of 20.3 indicates a reasonable valuation compared to its earnings.
- Gross Margin of 53.6% demonstrates efficient operations and strong pricing power in the surgical devices market.
- Dividend Yield of 1.09% provides a modest return for investors.
- Beta of 0.99 suggests the stock's volatility is similar to the overall market.
Who Are CNMD's Competitors?
CNMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| MDT Medtronic plc | $83.06 | -0.16% | 107B | 77 |
| SYK Stryker Corporation | $325.19 | -0.41% | $124.67B | 79 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.32M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNMD's Key Strengths?
- Established brands in orthopedic and general surgery.
- Proprietary technologies and innovative products.
- Direct sales force and distribution network.
- Strong relationships with surgeons and healthcare providers.
What Are CNMD's Weaknesses?
- Smaller market capitalization compared to major competitors.
- Reliance on specific surgical solutions.
- Potential vulnerability to pricing pressures.
- Limited geographic diversification.
What Could Drive CNMD Stock Higher?
- New product launches in orthopedic surgery segment.
- Expansion of sales and marketing efforts in emerging markets.
- Strategic acquisitions to broaden product portfolio.
- Development and commercialization of advanced endoscopic technologies.
What Are the Key Risks for CNMD?
- Financial-distress signal — its Altman Z-Score of 1.78 sits in the distress zone (elevated bankruptcy risk).
- Increased competition from larger medical device companies.
- Regulatory changes in the healthcare industry.
- Pricing pressures from hospitals and healthcare providers.
- Product liability claims.
- Dependence on key suppliers for critical components.
What Are the Growth Opportunities for CNMD?
- Expansion of Orthopedic Surgery Product Line: CONMED has the opportunity to further expand its orthopedic surgery product line, focusing on innovative solutions for soft tissue repair and minimally invasive procedures. The global orthopedic devices market is projected to reach $54.2 billion by 2028, presenting a significant growth opportunity. By investing in research and development and strategic acquisitions, CONMED can capture a larger share of this market and drive revenue growth. Timeline: Ongoing.
- Penetration of Emerging Markets: CONMED can drive growth by expanding its presence in emerging markets, where healthcare spending is increasing and demand for advanced surgical solutions is rising. These markets offer significant potential for revenue growth. CONMED can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets effectively. Timeline: Ongoing.
- Strategic Acquisitions: CONMED can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to innovative technologies. The medical devices industry is characterized by consolidation, and acquisitions can provide CONMED with a competitive advantage. By carefully selecting acquisition targets, CONMED can enhance its growth prospects and create shareholder value. Timeline: Ongoing.
- Development of Endoscopic Technologies: CONMED can focus on developing and commercializing advanced endoscopic technologies for gastroenterology procedures and the treatment of biliary structure diseases. The global endoscopy devices market is projected to reach $41.2 billion by 2027, presenting a significant growth opportunity. By investing in research and development and strategic partnerships, CONMED can capture a larger share of this market. Timeline: Ongoing.
- Increased Adoption of Minimally Invasive Surgery: The increasing adoption of minimally invasive surgical procedures is driving demand for CONMED's products. Minimally invasive surgery offers several benefits, including reduced pain, shorter hospital stays, and faster recovery times. By focusing on developing and marketing products that support minimally invasive surgery, CONMED can capitalize on this trend and drive revenue growth. Timeline: Ongoing.
What Opportunities Does CNMD Have?
- Expansion into emerging markets.
- Strategic acquisitions to broaden product portfolio.
- Development of advanced endoscopic technologies.
- Increased adoption of minimally invasive surgery.
What Threats Does CNMD Face?
- Competition from larger medical device companies.
- Regulatory changes in the healthcare industry.
- Pricing pressures from hospitals and healthcare providers.
- Product liability claims.
What Are CNMD's Competitive Advantages?
- Established brands (Hall, CONMED Linvatec, Concept, Shutt).
- Proprietary technologies in orthopedic and general surgery.
- Direct sales force and distribution network.
- Strong relationships with surgeons and healthcare providers.
What Does CNMD Do?
CONMED Corporation, incorporated in 1970 and headquartered in Largo, Florida, is a global medical technology company focused on the development, manufacturing, and sale of surgical devices and related equipment. The company's origins lie in addressing the evolving needs of surgeons and healthcare providers by offering innovative solutions for a range of surgical procedures. Over the years, CONMED has expanded its product portfolio through internal development and strategic acquisitions, establishing itself as a key player in the medical devices market. CONMED's product offerings are divided into two main categories: orthopedic surgery and general surgery. The orthopedic surgery segment includes products like the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, designed to aid in the repair of soft tissue injuries. These products are marketed under the Hall, CONMED Linvatec, Concept, and Shutt brands. The general surgery segment includes products for clinical insufflation, smoke evacuation, electrosurgical procedures, and endomechanical applications. Additionally, CONMED offers endoscopic technologies for gastroenterology procedures and products for treating biliary structure diseases, along with cardiac monitoring products like ECG and EEG electrodes and defibrillation pads. CONMED distributes its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors, ensuring broad market access and customer reach.
What Products and Services Does CNMD Offer?
- Develops surgical devices and related equipment.
- Manufactures surgical devices for orthopedic and general surgery.
- Sells surgical devices and equipment to hospitals and surgery centers.
- Offers orthopedic surgery products for soft tissue repair.
- Provides general surgery products for clinical insufflation and smoke evacuation.
- Markets endoscopic technologies for gastroenterology procedures.
- Offers cardiac monitoring products, including ECG and EEG electrodes.
How Does CNMD Make Money?
- Develops and manufactures surgical devices.
- Sells products directly to hospitals and surgery centers.
- Utilizes medical specialty distributors for market reach.
- Focuses on both orthopedic and general surgery solutions.
What Industry Does CNMD Operate In?
CONMED Corporation operates within the global medical devices industry, which is characterized by continuous innovation, increasing demand for minimally invasive procedures, and an aging global population. The industry is highly competitive, with major players like Johnson & Johnson, Medtronic, and Stryker dominating the market. CONMED differentiates itself through its focus on specific surgical solutions and its established brands. The medical devices industry is expected to continue growing, driven by technological advancements and increasing healthcare spending. CONMED's strategic focus on orthopedic and general surgery positions it well to capitalize on these trends.
Who Are CNMD's Key Customers?
- Hospitals
- Surgery centers
- Healthcare institutions
Company Profile
CONMED Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Largo, US. The company is led by CEO Patrick J. Beyer. CNMD has traded publicly since 1987.
ROE 5%Key Financial Metrics
Return on equity for CONMED Corporation stands at 5.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.4%, showing how much profit it generates from its asset base. CNMD trades at a trailing price-to-earnings ratio of 20.27, below the Healthcare sector average of ~23x. Its free cash flow yield is 12.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.5%, the inverse of the P/E and a quick read on earnings relative to price.
CNMD Valuation & Market Position
With a $1.07B market cap, CONMED Corporation sits in the small-cap segment of the market. Relative to its peer group, CNMD's quantitative score of 73/100 is roughly in line with the peer average of 78/100.
Quarterly Financial Performance: CONMED Corporation
Revenue for CONMED Corporation came in at $317.0M during Q1 2026, a 15.1% contraction versus the preceding quarter. The company recorded net income of $13.8M, with diluted EPS of $0.45. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CNMD averaged $0.44 in diluted EPS.
F-Score 9/9Financial Health
CONMED Corporation's Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.78 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project CONMED Corporation revenue of about $1.36B for fiscal 2026, with EPS near $4.37. The estimate reflects 4 contributing analysts.
CNMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in CONMED's future performance, indicating that key stakeholders see potential upside.
- Community sentiment has shifted positively, with increased discussions highlighting innovative product launches and their impact on market share.
- Analysts have noted improvements in operational efficiencies, which could enhance profitability in the coming quarters.
- The ongoing demand for surgical instruments and medical devices positions CONMED favorably in a growing healthcare market.
Bear Case
- Concerns over supply chain disruptions have been raised, potentially affecting product availability and revenue generation.
- Negative sentiment has emerged regarding valuation, with some community members feeling the stock is overvalued given current market conditions.
- Recent quarterly earnings reports showed slower growth than expected, leading to skepticism about future performance.
- Increased competition in the medical device sector could pressure CONMED's market position and profit margins.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $317M | $14M | $0.45 |
| Q4 2025 | $373M | $17M | $0.54 |
| Q3 2025 | $339M | $3M | $0.09 |
| Q2 2025 | $343M | $21M | $0.69 |
Based on FMP financials and quantitative analysis
CNMD Latest News
-
Is the Options Market Predicting a Spike in CONMED Stock?
zacks.com · May 14, 2026
-
[Latest] Global Flexible Endoscope Market Size/Share Worth USD 22.7 Billion by 2035 at a 6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Yahoo! Finance: CNMD News · May 11, 2026
-
Earnings Scheduled For April 29, 2026
benzinga · Apr 29, 2026
-
Earnings Scheduled For July 28, 2021
· Jul 28, 2021
CNMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNMD.
Price Targets
Wall Street price target analysis for CNMD.
CNMD MoonshotScore
What does this score mean?
The MoonshotScore rates CNMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Is the Options Market Predicting a Spike in CONMED Stock?
[Latest] Global Flexible Endoscope Market Size/Share Worth USD 22.7 Billion by 2035 at a 6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Earnings Scheduled For April 29, 2026
Earnings Scheduled For July 28, 2021
Leadership: Patrick J. Beyer
CEO
Patrick J. Beyer serves as the CEO of CONMED Corporation. His background includes extensive experience in the medical device industry, with a proven track record of driving growth and innovation. Prior to joining CONMED, Beyer held leadership positions at various medical technology companies, where he focused on strategic planning, product development, and market expansion. His expertise spans across multiple therapeutic areas, including orthopedics, general surgery, and endoscopy. Beyer's leadership is characterized by a commitment to customer satisfaction and a focus on delivering innovative solutions to meet the evolving needs of healthcare providers.
Track Record: Under Patrick J. Beyer's leadership, CONMED Corporation has focused on expanding its product portfolio through internal development and strategic acquisitions. He has overseen the introduction of new technologies and solutions in the orthopedic and general surgery segments. Beyer has also emphasized operational efficiency and cost management, contributing to improved profitability. His strategic decisions have positioned CONMED for continued growth and success in the competitive medical devices market.
CNMD Healthcare Stock FAQ
What does CONMED Corporation do?
CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers a comprehensive range of products for orthopedic surgery, including soft tissue repair solutions, and general surgery, encompassing clinical insufflation, smoke evacuation, and electrosurgical devices. CONMED markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors, focusing on providing innovative solutions to surgeons and healthcare providers.
What do analysts say about CNMD stock?
Analyst consensus on CNMD stock is mixed, with some firms maintaining a neutral rating and others suggesting a positive outlook. Key valuation metrics, such as the P/E ratio of 20.3, are considered in line with industry averages. Growth considerations include the company's ability to expand its product portfolio, penetrate emerging markets, and capitalize on the increasing demand for minimally invasive surgical procedures. However, analysts also note potential risks, such as competition from larger medical device companies and regulatory changes in the healthcare industry. No buy or sell recommendations are made here.
What are the main risks for CNMD?
The main risks for CONMED Corporation include increased competition from larger medical device companies, which could impact market share and pricing power. Regulatory changes in the healthcare industry, such as new product approval requirements or reimbursement policies, could also pose a risk. Additionally, pricing pressures from hospitals and healthcare providers, as well as potential product liability claims, could negatively affect the company's financial performance. Dependence on key suppliers for critical components also represents an ongoing risk.
What are the key factors to evaluate for CNMD?
CONMED Corporation (CNMD) holds an AI score of 73/100 (high). P/E: 20.3x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CNMD data refresh on this page?
CNMD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CNMD's recent stock price performance?
CONMED Corporation (CNMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brands in orthopedic and general surgery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNMD overvalued or undervalued right now?
CONMED Corporation (CNMD) trades at 20.3x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CNMD?
Before investing in CONMED Corporation (CNMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest reporting period.